NL8120466A - Werkwijze ter zuivering van polyosiden van streptococcus pneumoniae en vaccin op basis van aldus gezuiverde polyosiden. - Google Patents
Werkwijze ter zuivering van polyosiden van streptococcus pneumoniae en vaccin op basis van aldus gezuiverde polyosiden. Download PDFInfo
- Publication number
- NL8120466A NL8120466A NL8120466A NL8120466A NL8120466A NL 8120466 A NL8120466 A NL 8120466A NL 8120466 A NL8120466 A NL 8120466A NL 8120466 A NL8120466 A NL 8120466A NL 8120466 A NL8120466 A NL 8120466A
- Authority
- NL
- Netherlands
- Prior art keywords
- polyoside
- precipitate
- added
- solution
- phenol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 87
- 238000000746 purification Methods 0.000 title claims description 35
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims description 25
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims description 23
- 229960005486 vaccine Drugs 0.000 title claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 294
- 239000000243 solution Substances 0.000 claims description 147
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 125
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 123
- 239000002244 precipitate Substances 0.000 claims description 92
- 238000011282 treatment Methods 0.000 claims description 82
- 238000003756 stirring Methods 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 66
- 238000001556 precipitation Methods 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000012535 impurity Substances 0.000 claims description 33
- 239000008346 aqueous phase Substances 0.000 claims description 31
- 239000006228 supernatant Substances 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 230000009089 cytolysis Effects 0.000 claims description 23
- 238000000108 ultra-filtration Methods 0.000 claims description 21
- 238000000502 dialysis Methods 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 17
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 14
- 229910001424 calcium ion Inorganic materials 0.000 claims description 14
- 238000005352 clarification Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000008366 buffered solution Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229940124733 pneumococcal vaccine Drugs 0.000 claims description 3
- 238000005273 aeration Methods 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 241001478240 Coccus Species 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 149
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 51
- 229960000583 acetic acid Drugs 0.000 description 51
- 238000005119 centrifugation Methods 0.000 description 48
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 46
- 239000001632 sodium acetate Substances 0.000 description 46
- 235000017281 sodium acetate Nutrition 0.000 description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 230000001476 alcoholic effect Effects 0.000 description 32
- 239000007974 sodium acetate buffer Substances 0.000 description 32
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 238000010908 decantation Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 16
- 230000003544 deproteinization Effects 0.000 description 14
- 238000005199 ultracentrifugation Methods 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 229960001031 glucose Drugs 0.000 description 12
- 239000012510 hollow fiber Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- IPBVNPXQWQGGJP-UHFFFAOYSA-N phenyl acetate Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 244000052616 bacterial pathogen Species 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229960003964 deoxycholic acid Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 229930182830 galactose Natural products 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000206672 Gelidium Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000005141 Otitis Diseases 0.000 description 3
- 208000035109 Pneumococcal Infections Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000019258 ear infection Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical class O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000008273 hexosamines Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- MKPCNMXYTMQZBE-UHFFFAOYSA-N 7h-purin-6-amine;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.NC1=NC=NC2=C1NC=N2.NC1=NC=NC2=C1NC=N2 MKPCNMXYTMQZBE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001428214 Polyides Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003497 anti-pneumococcal effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940054666 biotin 0.15 mg Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 229940093680 calcium pantothenate 500 mg Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 ethanol) Chemical compound 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229940124959 polyvalent pneumococcal vaccine Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940097022 thiamine 100 mg Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8026320 | 1980-12-11 | ||
| FR8026320A FR2495939B1 (fr) | 1980-12-11 | 1980-12-11 | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| FR8100161 | 1981-12-11 | ||
| PCT/FR1981/000161 WO1982001995A1 (fr) | 1980-12-11 | 1981-12-11 | Procede de purification de polyosydes de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8120466A true NL8120466A (nl) | 1982-11-01 |
Family
ID=9248957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8120466A NL8120466A (nl) | 1980-12-11 | 1981-12-11 | Werkwijze ter zuivering van polyosiden van streptococcus pneumoniae en vaccin op basis van aldus gezuiverde polyosiden. |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE891444A (enExample) |
| CH (1) | CH662056A5 (enExample) |
| DE (1) | DE3152621T1 (enExample) |
| FR (1) | FR2495939B1 (enExample) |
| GB (1) | GB2102291B (enExample) |
| NL (1) | NL8120466A (enExample) |
| WO (1) | WO1982001995A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2160570T3 (es) * | 1988-12-16 | 2001-11-16 | Nederlanden Staat | Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos. |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| PT3466982T (pt) * | 2005-04-08 | 2020-07-24 | Wyeth Llc | Separação de contaminantes do polissacárido de streptococcus pneumoniae por manipulação do ph |
| AU2008231041B2 (en) * | 2007-03-23 | 2013-03-07 | Wyeth Llc | Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides |
| HUE037465T2 (hu) | 2008-12-18 | 2018-09-28 | Wyeth Llc | Eljárás 19A szerotípusú streptococcus pneumoniae poliszacharidok molekulatömegének szabályozására |
| AU2009335824B2 (en) | 2008-12-18 | 2013-07-04 | Wyeth Llc | Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon |
| WO2011151841A1 (en) * | 2010-05-31 | 2011-12-08 | Panacea Biotec Limited | Fermentation process for streptococcus pneumoniae |
| EP3140429B1 (en) | 2014-05-05 | 2020-02-19 | Medtronic Inc. | Methods for scd, crt, crt-d, or sca therapy identification and/or selection |
| GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
| GB2614916A (en) | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2388563A1 (fr) * | 1977-04-29 | 1978-11-24 | Fabre Sa Pierre | Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires |
-
1980
- 1980-12-11 FR FR8026320A patent/FR2495939B1/fr not_active Expired
-
1981
- 1981-12-11 BE BE0/206808A patent/BE891444A/fr not_active IP Right Cessation
- 1981-12-11 DE DE813152621T patent/DE3152621T1/de active Granted
- 1981-12-11 GB GB08223061A patent/GB2102291B/en not_active Expired
- 1981-12-11 NL NL8120466A patent/NL8120466A/nl unknown
- 1981-12-11 CH CH4795/82A patent/CH662056A5/fr not_active IP Right Cessation
- 1981-12-11 WO PCT/FR1981/000161 patent/WO1982001995A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2495939A1 (fr) | 1982-06-18 |
| FR2495939B1 (fr) | 1985-10-11 |
| GB2102291A (en) | 1983-02-02 |
| CH662056A5 (fr) | 1987-09-15 |
| WO1982001995A1 (fr) | 1982-06-24 |
| DE3152621T1 (de) | 1983-11-17 |
| DE3152621C2 (enExample) | 1988-05-11 |
| GB2102291B (en) | 1985-07-24 |
| BE891444A (fr) | 1982-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4220717A (en) | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. | |
| US4578458A (en) | Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa | |
| NL8120466A (nl) | Werkwijze ter zuivering van polyosiden van streptococcus pneumoniae en vaccin op basis van aldus gezuiverde polyosiden. | |
| EP0157899A2 (en) | Multivalent pneumococcal vaccine and preparation thereof | |
| JPS60251898A (ja) | 醗酵法によるヒアルロン酸の製造方法 | |
| EP0041897B1 (en) | Polysaccharide antigen from streptococcus and vaccines | |
| EP0038265B1 (en) | Group b streptococcal capsular polysaccharides | |
| US4413057A (en) | Group B streptococcal capsular polysaccharides | |
| US5116963A (en) | High-purity dermatan sulphate | |
| CZ20012694A3 (cs) | Způsob čiątění kyseliny hyalurové o vysoké molekulové hmotnosti | |
| Barbarić et al. | Role of the carbohydrate part of yeast acid phosphatase | |
| EP0407037A1 (en) | Process for removing bacterial endotoxin from gram-negative polysaccharides | |
| IE47149B1 (en) | Vaccine | |
| EP0015846A2 (en) | Antigenic sub-cellular cell wall fraction of Bordetella Bronchiseptica, method of obtaining it and composition comprising it | |
| US4302445A (en) | Method for concentrating and purifying antihemophilic factor or factor VIII | |
| AU5447398A (en) | Method for conversion of blood type | |
| CN117756959A (zh) | 一种肺炎链球菌荚膜多糖的制备方法 | |
| US4264764A (en) | Meningitis vaccine | |
| CN115161207A (zh) | 半乳糖酵母液的制备方法、半乳糖酵母粉及在亮肤淡化皱纹的应用 | |
| FI79140B (fi) | Foerfarande foer framstaellning av ett tf-500-aemne med karsinostatisk och immunitet stimulerande aktivitet. | |
| IT8247817A1 (it) | Sostenze carcinostatiche ed immunostimolanti tf-2, procedimento per prepararle ed agente carcinostatico che le contiene | |
| JPH0455675B2 (enExample) | ||
| JPS6324977B2 (enExample) | ||
| CN116617462A (zh) | 一种中性环境水溶性脱细胞真皮基质材料、其制备方法以及其应用 | |
| DK151639B (da) | Fremgangsmaade til fremstilling af tf-100 eller fraktioner heraf med carcinostatisk og immunostimulerende aktivitet |